Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2014
03/27/2014WO2014046472A1 Medicine having improved rivastigmine stability
03/27/2014WO2014046441A1 Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same
03/27/2014WO2014046391A1 Pharmaceutical composition for treating or preventing ptpσ-mediated diseases
03/27/2014WO2014046224A1 Coumarin derivative
03/27/2014WO2014046191A1 Local-anesthetic long-lasting sustained-release liposome preparation
03/27/2014WO2014046129A1 Pharmaceutical composition for oral administration with improved elution and/or absorbency
03/27/2014WO2014046125A1 Prevention/treatment agent for pulmonary hypertension comprising thrombin receptor antagonist as active component
03/27/2014WO2014046065A1 Advanced heart failure treatment material as myocardial/cardiovascular regeneration device
03/27/2014WO2014045961A1 Therapeutic agent for dermatomycosis
03/27/2014WO2014045561A1 Novel carotenoid
03/27/2014WO2014045310A1 Pyrimido[5,4-d]pyrimidine or pyrimidine derivatives compounds and uses thereof in the treatment of cancer
03/27/2014WO2014045305A1 Substituted fused tricyclic compounds, compositions and medicinal applications thereof
03/27/2014WO2014045283A1 Restoration of the cftr function by splicing modulation
03/27/2014WO2014045162A1 ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
03/27/2014WO2014045156A1 Novel bicyclic pyridinones
03/27/2014WO2014045101A1 Tetrazolo quinoxaline derivatives as tankyrase inhibitors
03/27/2014WO2014045046A2 Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
03/27/2014WO2014045031A1 Bicyclic aza compounds as muscarinic m1 receptor agonists
03/27/2014WO2014045029A1 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
03/27/2014WO2014044972A1 Treatment of motor neuronopathies
03/27/2014WO2014044896A1 Orodispersible pharmaceutical composition of melatonin
03/27/2014WO2014044869A2 Medical preparation comprising a carrier and polyhexanide or octenidine
03/27/2014WO2014044849A1 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
03/27/2014WO2014044848A1 Methods for predicting multiple myeloma treatment response
03/27/2014WO2014044846A1 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
03/27/2014WO2014044836A1 Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis
03/27/2014WO2014044790A1 Methods and pharmaceutical compositions for the treatment and prevention of hypothyroidism in down syndrome (ds) patients
03/27/2014WO2014044757A1 Cationic triphenylamine derivatives activable by visible and infra red light for inducing and imaging apoptosis in cancer cells
03/27/2014WO2014044755A1 4-(indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/27/2014WO2014044754A1 4-indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/27/2014WO2014044738A1 Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators
03/27/2014WO2014044721A1 Novel crystalline form of vortioxetine hydrobromide
03/27/2014WO2014044691A1 Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors
03/27/2014WO2014044645A1 Macrolide derivatives, preparation thereof and therapeutic use thereof
03/27/2014WO2014044622A1 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
03/27/2014WO2014044611A1 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration
03/27/2014WO2014044591A1 Composition comprising plant phenols for preventing or reducing tewl and associated disorders and diseases
03/27/2014WO2014044399A1 New spiroepoxide tetrahydrobenzotriazoles and their use as metap-ii inhibitors
03/27/2014WO2014044356A1 Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors
03/27/2014WO2014044113A1 Pyrazol[3,4-c] pyridine derivative, preparation method and use in medicine thereof
03/27/2014WO2014044107A1 Pyrazol[3,4-c] pyridine derivative, preparation method and use in medicine thereof
03/27/2014WO2014044028A1 Anti lung cancer drug made of oleum cassiae and major constituent cinnamaldehyde thereof and use thereof
03/27/2014WO2014044025A1 Pyrimidineamide derivative and preparation method and use thereof
03/27/2014WO2014043895A1 2-hydroxyl tetrahydro thienopyridine derivative with optical activity and preparation method and use thereof
03/27/2014WO2014043866A1 Thiophene [2, 3-d] pyrimidine derivative, and preparation method and use thereof
03/27/2014WO2014043793A1 Cmpf as a biomarker for diabetes and associated methods
03/27/2014WO2014043792A1 Glucosamine pro-drugs
03/27/2014WO2014020574A3 Improved process for the preparation of calcimimetics
03/27/2014WO2014020546A3 Crystalline forms of dabigatran etexilate and process for their preparation
03/27/2014WO2014019908A3 Substituted pyrroles active as kinases inhibitors
03/27/2014WO2014017900A3 Novel bioactive compound obtained from oil palm base materials
03/27/2014WO2014016848A3 Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
03/27/2014WO2014014900A8 Histone deacetylase inhibitors and compositions and methods of use thereof
03/27/2014WO2014006528A3 Compositions and methods for the treatment of neurological degenerative disorders
03/27/2014WO2013184036A3 Hepatoprotective agent
03/27/2014WO2013181579A3 Tetrahydropyrazolopyrimidine compounds
03/27/2014WO2013171535A3 Agent for inhibiting odor of pyrazine derivatives
03/27/2014WO2013151744A9 Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
03/27/2014WO2013130669A8 Pharmaceutical composition and administration thereof
03/27/2014WO2013061205A8 (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
03/27/2014WO2013036232A3 Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
03/27/2014WO2012154676A9 Partially saturated tricyclic compounds and methods of making and using same
03/27/2014WO2012037349A3 Compounds
03/27/2014WO2012037320A3 Pharmaceutical compositions
03/27/2014WO2012037299A3 Fatty acid synthase inhibitors
03/27/2014WO2012037119A3 Inhibitors of viral entry into mammalian cells
03/27/2014WO2012033938A3 Identification of pcna targeting compounds for cancer therapy and pcna function regulation
03/27/2014WO2012018662A3 Fused-imidazoyl compounds useful as antimicrobial agents
03/27/2014WO2012009542A3 Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
03/27/2014WO2012009290A3 Formulations for the treatment of urushiol-induced contact dermatitis
03/27/2014WO2012008999A3 Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
03/27/2014WO2012006584A3 Therapeutic regimens for hedgehog-associated cancers
03/27/2014WO2011127192A3 Antimetastatic compounds
03/27/2014WO2011087738A3 1,4-substituted piperazine derivatives and methods of use thereof
03/27/2014WO2011044523A3 Compositions and methods for treating obesity
03/27/2014WO2011005566A3 Aptamer-targeted sirna to inhibit nonsense mediated decay
03/27/2014WO2010127108A3 Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
03/27/2014US20140088669 Particles
03/27/2014US20140088502 Multi-Needle Injection Apparatus and System for Delivering Pharmacological Agents to Biological Tissue
03/27/2014US20140088199 Ophthalmic treatments
03/27/2014US20140088197 Mixed crystal agomelatine (form viii), preparation method and use thereof and pharmaceutical composition containing same
03/27/2014US20140088194 Stable pharmaceutical composition and methods of using same
03/27/2014US20140088193 Viral inhibitor composition for in vivo therapeutic use
03/27/2014US20140088192 Subcutaneously infusible levodopa prodrug compositions and methods of infusion
03/27/2014US20140088191 Inhibition of Renal Fibrosis
03/27/2014US20140088189 Methods for reducing the risk of an adverse dronedarone / beta-blockers interaction in a patient suffering from atrial fibrilation
03/27/2014US20140088186 Composition containing arylnaphthalene lignan derivative for preventing and/or treating dementia
03/27/2014US20140088185 Method of treating digestive upsets by buccal administration of botanical derivatives
03/27/2014US20140088184 Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus
03/27/2014US20140088183 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
03/27/2014US20140088182 Inflammatory eye disease
03/27/2014US20140088181 Taxane Pro-Emulsion Formulations and Methods Making and Using the Same
03/27/2014US20140088178 Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
03/27/2014US20140088176 Gene transfer for regulating smooth muscle tone
03/27/2014US20140088171 Agents for treating disorders involving modulation of ryanodine receptors
03/27/2014US20140088168 Anticonvulsant combination therapy
03/27/2014US20140088166 Process of making and using pharmaceutical formulations of antineoplastic agents
03/27/2014US20140088164 Pharmaceutical Compositions
03/27/2014US20140088162 Treatment of Pulmonary Hypertension with Carbonic Anhydrase Inhibitors
03/27/2014US20140088161 Use of a feed composition for reducing methane emission in ruminants, and/or to improve ruminant performance
1 ... 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 ... 7860